Equities analysts expect Alimera Sciences Inc (NASDAQ:ALIM) to announce $11.27 million in sales for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Alimera Sciences’ earnings. The lowest sales estimate is $10.90 million and the highest is $11.64 million. Alimera Sciences reported sales of $9.78 million in the same quarter last year, which indicates a positive year-over-year growth rate of 15.2%. The firm is scheduled to announce its next quarterly earnings report on Wednesday, November 7th.
According to Zacks, analysts expect that Alimera Sciences will report full year sales of $43.51 million for the current fiscal year, with estimates ranging from $42.80 million to $44.21 million. For the next year, analysts forecast that the company will report sales of $55.49 million, with estimates ranging from $50.70 million to $60.28 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of analysts that that provide coverage for Alimera Sciences.
Alimera Sciences (NASDAQ:ALIM) last posted its quarterly earnings data on Monday, July 30th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.06). The firm had revenue of $10.92 million during the quarter, compared to analyst estimates of $10.78 million.
ALIM stock traded down $0.04 during trading on Friday, hitting $0.98. The stock had a trading volume of 132,800 shares, compared to its average volume of 157,028. The company has a current ratio of 3.85, a quick ratio of 3.61 and a debt-to-equity ratio of -0.60. Alimera Sciences has a twelve month low of $0.74 and a twelve month high of $1.46. The stock has a market cap of $73.54 million, a price-to-earnings ratio of -3.52 and a beta of 1.52.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. lifted its stake in Alimera Sciences by 28.5% in the 2nd quarter. BlackRock Inc. now owns 272,248 shares of the biopharmaceutical company’s stock worth $266,000 after purchasing an additional 60,327 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of Alimera Sciences by 20.8% during the 2nd quarter. Renaissance Technologies LLC now owns 574,000 shares of the biopharmaceutical company’s stock valued at $562,000 after buying an additional 99,000 shares during the period. Finally, Stonepine Capital Management LLC raised its position in shares of Alimera Sciences by 13.0% during the 2nd quarter. Stonepine Capital Management LLC now owns 6,981,184 shares of the biopharmaceutical company’s stock valued at $6,830,000 after buying an additional 801,151 shares during the period. 51.85% of the stock is currently owned by institutional investors and hedge funds.
Alimera Sciences Company Profile
Alimera Sciences, Inc, a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness.
Featured Article: How Do You Calculate Return on Investment (ROI)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.